ACRO Biomedical Co Ltd
Acro Biomedical Co., Ltd. engages in the development and marketing of nutritional products in Indiana and internationally. It is involved in the development and sale of cordyceps related products, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. wa… Read more
ACRO Biomedical Co Ltd (ACBM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.126x
Based on the latest financial reports, ACRO Biomedical Co Ltd (ACBM) has a cash flow conversion efficiency ratio of 0.126x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-54.41K) by net assets ($-432.62K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ACRO Biomedical Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how ACRO Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ACRO Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACRO Biomedical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ACTIA GROUP SA INH.EO-75
F:AG9
|
N/A |
|
BIT Computer
KO:032850
|
0.006x |
|
PERSEUS MINING - Dusseldorf Stock Exchang
DU:P4Q
|
N/A |
|
Tian Ruixiang Holdings Ltd
NASDAQ:TIRX
|
-0.083x |
|
NEW HOPE CORPN (OD8.SG)
STU:OD8
|
N/A |
|
Braxia Scientific Corp
PINK:BRAXF
|
1.456x |
|
VLID3F
SA:VLID3F
|
N/A |
|
Ji Tech Co. Ltd.
KO:417500
|
N/A |
Annual Cash Flow Conversion Efficiency for ACRO Biomedical Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of ACRO Biomedical Co Ltd from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-312.85K | $-196.30K | 0.627x | +404.43% |
| 2024-12-31 | $-294.97K | $-36.69K | 0.124x | +141.02% |
| 2023-12-31 | $486.37K | $-147.48K | -0.303x | 0.00% |
| 2022-12-31 | $486.37K | $-147.48K | -0.303x | -165.21% |
| 2021-12-31 | $643.71K | $299.33K | 0.465x | +259.90% |
| 2020-12-31 | $685.87K | $-199.46K | -0.291x | -288.78% |
| 2019-12-31 | $798.24K | $-59.71K | -0.075x | +33.83% |
| 2018-12-31 | $1.24 Million | $-140.42K | -0.113x | +87.52% |
| 2017-12-31 | $511.33K | $-463.34K | -0.906x | -138.58% |
| 2016-12-31 | $-14.79K | $-34.74K | 2.349x | +237.67% |
| 2015-12-31 | $28.64K | $-48.85K | -1.706x | -- |